Amir Hefni | VP, Global Commercial Head, Cell & Gene

Amir Hefni, VP, Global Commercial Head, Cell & Gene, Novartis

Amir Hefni is Vice President and Global Commercial Head for Cell & Gene, having joined Novartis in May 2020. He leads the global commercialisation of Cell & Gene therapies for Novartis Oncology.  Amir joined Novartis from Ipsen, where he was Oncology Brand Global General Manager and led the launch of multiple indications across the globe as well as drove a rich Life Cycle Management program. Previously, he was with Bristol-Myers Squibb (BMS) for 11 years, roles included Executive Director, US Oncology Thoracic Lead, where he led NSCLC, SCLC, and SCCHN. Furthermore, Amir brings a wealth of experience working across different countries including US, UK/Ireland and Sweden. He held various leadership positions at BMS: from Business Unit Head in the UK/Ireland to roles within the Worldwide Commercial group, General Manager in Sweden and International Markets Strategy & Operations. Amir holds a BSc and PhD in Pharmacology from King?s College London, University of London (UK) and a MBA from Warwick Business School, University of Warwick (UK). He also completed the General Management Program at INSEAD in 2017.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 11:30

Keynote panel discussion: State of the industry panel

  • How have events over the last 12 months affected the industry? Maintaining
  • Where is the ATMP field headed?
  • Who is making the best progress?
  • What is new on the market?
  • The Next Wave: moving beyond CAR-T and Gene Therapy, what’s next?

Day 2: Thursday 20th May 2021 - Gene Therapy @ 12:00

Keynote panel discussion: Where are we with COVID now?

·There are 70+ CT clinical trials registered for COVID and ARDS related to COVID·Round up of COVID & ARDs related CT clinical trials·What are the short term and long-term effects of COVID on the industry going forward?·Head to head comparison of data from key players·Regulatory standpoint on cell therapies for COVID ARDs

Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 13:00

Keynote panel discussion: Finding the right framework for reimbursement and market access for cell and gene therapies

·Europe vs USA vs ROW?·Reimbursement strategies·What’s driving the decision makers at country and national level?
last published: 10/May/21 08:45 GMT

back to speakers